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Introduction {#embj2018101199-sec-0001}
============

Bacterial antisense RNAs were initially found and described as regulators in accessory elements: plasmids, phages, and transposons (Wagner *et al*, [2002](#embj2018101199-bib-0104){ref-type="ref"}; Wagner & Romby, [2015](#embj2018101199-bib-0087){ref-type="ref"}). These *cis*‐encoded antisense RNAs are encoded overlapping---in opposite orientation---their single target genes and thus have complete complementarity (Waters & Storz, [2009](#embj2018101199-bib-0089){ref-type="ref"}; Wagner & Romby, [2015](#embj2018101199-bib-0087){ref-type="ref"}; and references therein). Subsequently, numerous chromosomally encoded so‐called small RNAs (sRNAs) were discovered and are part of a large repertoire of post‐transcriptional regulators in all bacteria and archaea (Beisel & Storz, [2010](#embj2018101199-bib-0004){ref-type="ref"}; Gottesman & Storz, [2011](#embj2018101199-bib-0022){ref-type="ref"}; Barquist & Vogel, [2015](#embj2018101199-bib-0002){ref-type="ref"}; Wagner & Romby, [2015](#embj2018101199-bib-0087){ref-type="ref"}; Holmqvist & Wagner, [2017](#embj2018101199-bib-0031){ref-type="ref"}). This heterogeneous class of RNAs impacts on global regulatory circuits in metabolism, virulence, stress responses, and motility/biofilm formation decisions. A striking feature involves targeting of multiple genes within the same network. This relies on properties of *trans‐*encoded sRNAs: Since many sRNA genes do not overlap with target genes, base‐pairing is non‐contiguous and limited. Bacterial sRNAs can promote translational activation or, more frequently, repression (Papenfort & Vanderpool, [2015](#embj2018101199-bib-0058){ref-type="ref"}; Wagner & Romby, [2015](#embj2018101199-bib-0087){ref-type="ref"}; Carrier *et al*, [2018](#embj2018101199-bib-0010){ref-type="ref"}). Furthermore, target mRNAs can become stabilized or undergo facilitated decay (Lalaouna *et al*, [2013](#embj2018101199-bib-0038){ref-type="ref"}; Papenfort *et al*, [2013](#embj2018101199-bib-0057){ref-type="ref"}).

In many but not all bacteria, *trans‐*encoded sRNAs require the RNA chaperone Hfq for efficient regulation (Vogel & Luisi, [2011](#embj2018101199-bib-0085){ref-type="ref"}; Holmqvist & Vogel, [2018](#embj2018101199-bib-0032){ref-type="ref"}; Woodson *et al*, [2018](#embj2018101199-bib-0090){ref-type="ref"}). Hfq is a ring‐like homohexamer with at least three distinct RNA‐binding surfaces (Updegrove *et al*, [2016](#embj2018101199-bib-0079){ref-type="ref"}; Santiago‐Frangos & Woodson, [2018](#embj2018101199-bib-0072){ref-type="ref"}). The distal face of *Escherichia coli* Hfq recognizes A‐rich sequences, or (AAN)~n~ motifs, and primarily binds mRNAs (Link *et al*, [2009](#embj2018101199-bib-0042){ref-type="ref"}; Robinson *et al*, [2014](#embj2018101199-bib-0066){ref-type="ref"}). In contrast, most sRNAs bind the proximal face via the poly‐U tails of their Rho‐independent terminators (Otaka *et al*, [2011](#embj2018101199-bib-0054){ref-type="ref"}; Ishikawa *et al*, [2012](#embj2018101199-bib-0034){ref-type="ref"}), with specific recognition of the 3′ hydroxyl group (Sauer & Weichenrieder, [2011](#embj2018101199-bib-0073){ref-type="ref"}). Additional contacts are provided between internal U/A sequences and arginine patches on the lateral binding surface/rim (Sauer *et al*, [2012](#embj2018101199-bib-0074){ref-type="ref"}). Enterobacterial Hfq also carries intrinsically disordered C‐terminal domains (CTD; Beich‐Frandsen *et al*, [2011](#embj2018101199-bib-0003){ref-type="ref"}) whose function has been controversial. CTDs may aid recruitment of sRNAs, specifically RydC, to Hfq (Dimastrogiovanni *et al*, [2014](#embj2018101199-bib-0017){ref-type="ref"}). A recent study suggests their importance for the rapid release of bound RNAs (Santiago‐Frangos *et al*, [2016](#embj2018101199-bib-0071){ref-type="ref"}). Overall, Hfq is regarded as a platform on which RNAs meet for interaction. For this to happen on a biologically relevant timescale, RNAs must rapidly exchange on the limiting Hfq pool. RNA concentration‐driven cycling on Hfq has strong support from *in vitro* and *in vivo* experiments (Fender *et al*, [2010](#embj2018101199-bib-0018){ref-type="ref"}; Salim & Feig, [2010](#embj2018101199-bib-0070){ref-type="ref"}; Hussein & Lim, [2011](#embj2018101199-bib-0033){ref-type="ref"}; Moon & Gottesman, [2011](#embj2018101199-bib-0051){ref-type="ref"}; Olejniczak, [2011](#embj2018101199-bib-0053){ref-type="ref"}; Wagner, [2013](#embj2018101199-bib-0086){ref-type="ref"}).

Interaction with Hfq protects many RNAs from rapid degradation (Moll *et al*, [2003a](#embj2018101199-bib-0048){ref-type="ref"}; Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}) and promotes the annealing of sRNAs and their mRNA targets (Møller *et al*, [2002](#embj2018101199-bib-0050){ref-type="ref"}; Zhang *et al*, [2002](#embj2018101199-bib-0093){ref-type="ref"}; Lease & Woodson, [2004](#embj2018101199-bib-0039){ref-type="ref"}; Fender *et al*, [2010](#embj2018101199-bib-0018){ref-type="ref"}; Wroblewska & Olejniczak, [2016](#embj2018101199-bib-0091){ref-type="ref"}). Several non‐exclusive models suggest how Hfq can facilitate intermolecular base‐pairing. Simultaneous binding of two RNA molecules to an Hfq hexamer could help their interaction through "molecular crowding" (Rajkowitsch & Schroeder, [2007](#embj2018101199-bib-0064){ref-type="ref"}). Hfq binding may also entail structural rearrangements in RNAs, to unfold an otherwise inaccessible seed sequence in an sRNA (Zhang *et al*, [2002](#embj2018101199-bib-0093){ref-type="ref"}; Gorski *et al*, [2017](#embj2018101199-bib-0021){ref-type="ref"}) or possibly a sequestered target sequence in an mRNA. The latter has previously been proposed for *sodB* mRNA (Geissmann & Touati, [2004](#embj2018101199-bib-0019){ref-type="ref"}), but, as will be detailed in the [Discussion](#embj2018101199-sec-0010){ref-type="sec"}, lacks unambiguous experimental support and has been challenged (Hao *et al*, [2011](#embj2018101199-bib-0026){ref-type="ref"}). Another mechanism specifically moves the seed region of an sRNA into close proximity to its complement in the mRNA (Vogel & Luisi, [2011](#embj2018101199-bib-0085){ref-type="ref"}; Gorski *et al*, [2017](#embj2018101199-bib-0021){ref-type="ref"}). For example, the *rpoS* mRNA folds around Hfq, through contacts with distal and rim surfaces, into a compact ternary structure that positions the base‐pairing region adjacent to the complementary site within the sRNA DsrA (Peng *et al*, [2014a](#embj2018101199-bib-0060){ref-type="ref"},[b](#embj2018101199-bib-0061){ref-type="ref"}). Interaction with the Hfq rim can also position sRNAs for optimal base‐pairing, as shown for RydC‐*cfa* (Dimastrogiovanni *et al*, [2014](#embj2018101199-bib-0017){ref-type="ref"}). Besides positioning RNAs for interaction, the conserved arginine patches on the Hfq rim apparently play a role in duplex formation by overcoming electrostatic barriers to helix nucleation (Panja *et al*, [2013](#embj2018101199-bib-0055){ref-type="ref"}, [2015](#embj2018101199-bib-0056){ref-type="ref"}).

We and others have been interested in two sequence‐similar sRNAs, OmrA and OmrB, which act on multiple target mRNAs to regulate outer membrane and surface protein expression (Guillier & Gottesman, [2006](#embj2018101199-bib-0023){ref-type="ref"}, [2008](#embj2018101199-bib-0024){ref-type="ref"}; Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}; Mika & Hengge, [2014](#embj2018101199-bib-0047){ref-type="ref"}; Brosse *et al*, [2016](#embj2018101199-bib-0008){ref-type="ref"}; Jagodnik *et al*, [2017](#embj2018101199-bib-0035){ref-type="ref"}). Their genes (Argaman *et al*, [2001](#embj2018101199-bib-0001){ref-type="ref"}; Wassarman *et al*, [2001](#embj2018101199-bib-0088){ref-type="ref"}; Vogel *et al*, [2003](#embj2018101199-bib-0083){ref-type="ref"}) are transcriptionally activated by the OmpR‐EnvZ two‐component system, e.g., under high osmolarity conditions (Guillier & Gottesman, [2006](#embj2018101199-bib-0023){ref-type="ref"}; Brosse *et al*, [2016](#embj2018101199-bib-0008){ref-type="ref"}). OmrA, but not OmrB, is additionally under the control of the stress sigma factor σ^s^ (*rpoS*; Lévi‐Meyrueis *et al*, [2014](#embj2018101199-bib-0040){ref-type="ref"}; Peano *et al*, [2015](#embj2018101199-bib-0059){ref-type="ref"}; Colgan *et al*, [2016](#embj2018101199-bib-0014){ref-type="ref"}). Both sRNAs associate with Hfq *in vitro* (Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}) and *in vivo* (Wassarman *et al*, [2001](#embj2018101199-bib-0088){ref-type="ref"}; Zhang *et al*, [2003](#embj2018101199-bib-0094){ref-type="ref"}; Chao *et al*, [2012](#embj2018101199-bib-0011){ref-type="ref"}; Tree *et al*, [2014](#embj2018101199-bib-0078){ref-type="ref"}; Holmqvist *et al*, [2016](#embj2018101199-bib-0030){ref-type="ref"}); the sRNAs are destabilized in ∆*hfq* cells (Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}). OmrA and OmrB are redundant on most targets, using their almost identical 5′ tails for base‐pairing. Some validated target mRNAs encode the outer membrane proteins CirA and OmpT*,* their own activator OmpR (Guillier & Gottesman, [2008](#embj2018101199-bib-0024){ref-type="ref"}), the flagellar regulator FlhD (De Lay & Gottesman, [2012](#embj2018101199-bib-0016){ref-type="ref"})*,* and CsgD (Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}), the master transcriptional activator of the genes for the biofilm components curli and cellulose (Hammar *et al*, [1995](#embj2018101199-bib-0025){ref-type="ref"}; Römling, [2005](#embj2018101199-bib-0068){ref-type="ref"}). The regulation of *csgD* by OmrA and OmrB (Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}) and by four subsequently reported sRNAs (Jørgensen *et al*, [2012](#embj2018101199-bib-0036){ref-type="ref"}; Mika *et al*, [2012](#embj2018101199-bib-0045){ref-type="ref"}; Thomason *et al*, [2012](#embj2018101199-bib-0077){ref-type="ref"}; Bordeau & Felden, [2014](#embj2018101199-bib-0006){ref-type="ref"}) has highlighted the importance of tight regulation of biofilm formation. In addition to post‐transcriptional control by sRNAs, *csgD* expression is extensively regulated at the level of transcription, e.g., by the OmrAB‐regulated transcription factor OmpR, and DgcM (previously: YdaM; Hengge *et al*, [2015](#embj2018101199-bib-0028){ref-type="ref"}; Fig [1](#embj2018101199-fig-0001){ref-type="fig"}A). DgcM, a c‐di‐GMP‐producing diguanylate cyclase (DGC), is part of a c‐di‐GMP‐dependent switching module involved in the signaling cascade that controls curli synthesis. The phosphodiesterase (PDE) PdeR (a.k.a. YciR) directly inhibits DgcM until the levels of the second messenger c‐di‐GMP are sufficient for it to function as a PDE. DgcM then produces more c‐di‐GMP and, through a double‐negative feedback loop, activates MlrA (Lindenberg *et al*, [2013](#embj2018101199-bib-0041){ref-type="ref"}). DgcM, MlrA, and σ^s^ are all required for transcription of *csgD*. CsgD in turn activates transcription of the c*sgBAC* operon that encodes curli proteins (Hammar *et al*, [1995](#embj2018101199-bib-0025){ref-type="ref"}; Fig [1](#embj2018101199-fig-0001){ref-type="fig"}A).

![A new OmrA and OmrB target, in addition to *csgD* and *ompR*, that affects curli synthesis\
Schematic overview of part of the biofilm regulatory network, highlighting the roles of OmrA and OmrB. Gray arrows: transcriptional activation, black lines with bars: post‐transcriptional negative regulation, dotted lines: direct protein--protein or protein--c‐di‐GMP interactions.Congo red plates with colonies of *Escherichia coli* strain MC4100 *relA* ^+^ and its target mutation *csgD:M4--ompR:mut2* derivative, harboring sRNA‐producing plasmids pOmrA, pOmrB, or an empty vector (pControl). Incubation at 28°C for 48 h.Schematic showing published interaction sites between OmrA or OmrB and targets *csgD* or *ompR* (Guillier & Gottesman, [2008](#embj2018101199-bib-0024){ref-type="ref"}; Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}). Mutations introduced to disrupt base‐pairing are in gray boxes.](EMBJ-38-e101199-g002){#embj2018101199-fig-0001}

In this study, we identified *dgcM* as an additional OmrA/B target, upstream in the curli/biofilm pathway. Unexpectedly, our results suggest a new mechanism by which Hfq promotes regulation. Here, rather than acting canonically as a platform for simultaneous interactions that facilitate sRNA‐mRNA pairing, Hfq is primarily needed to render the mRNA target accessible for sRNA binding.

Results {#embj2018101199-sec-0002}
=======

OmrA and OmrB have multiple targets in the same regulatory pathway {#embj2018101199-sec-0003}
------------------------------------------------------------------

We previously showed that OmrA/B inhibit the synthesis of CsgD (Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}). OmrA/B also repress the synthesis of OmpR (Guillier & Gottesman, [2008](#embj2018101199-bib-0024){ref-type="ref"}), a transcriptional activator of *csgD* (Römling *et al*, [1998](#embj2018101199-bib-0067){ref-type="ref"}; Vidal *et al*, [1998](#embj2018101199-bib-0082){ref-type="ref"}; Prigent‐Combaret *et al*, [2001](#embj2018101199-bib-0063){ref-type="ref"}; Gerstel *et al*, [2003](#embj2018101199-bib-0020){ref-type="ref"}; Ogasawara *et al*, [2010](#embj2018101199-bib-0052){ref-type="ref"}; Fig [1](#embj2018101199-fig-0001){ref-type="fig"}A). As a result of the dual repression of these biofilm activators, ectopic overexpression of OmrA or OmrB downregulates curli production, resulting in white colonies on Congo red indicator plates (Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}; Fig [1](#embj2018101199-fig-0001){ref-type="fig"}B). In an attempt to render curli production independent of OmrA/B, we introduced chromosomal point mutations in *csgD* and *ompR* mRNAs that disrupt base‐pairing with both sRNAs (Guillier & Gottesman, [2008](#embj2018101199-bib-0024){ref-type="ref"}; Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}; Fig [1](#embj2018101199-fig-0001){ref-type="fig"}C). Surprisingly, these mutations failed to suppress the OmrA/B‐dependent inhibition of curli production, as overexpression of the sRNAs still gave white colonies on the indicator plates (Fig [1](#embj2018101199-fig-0001){ref-type="fig"}B and [Appendix Fig S1](#embj2018101199-sup-0001){ref-type="supplementary-material"}). This suggested that OmrA/B may inhibit curli formation not only through *csgD* and *ompR*, but also other targets.

OmrA and OmrB inhibit DgcM synthesis through direct base‐pairing interactions {#embj2018101199-sec-0004}
-----------------------------------------------------------------------------

Computational predictions of base‐pairing between OmrA or OmrB and mRNAs from biofilm‐associated genes (IntaRNA algorithm; Busch *et al*, [2008](#embj2018101199-bib-0009){ref-type="ref"}) indicated an interaction between the 5′‐tails of OmrA/OmrB and nucleotides 91--102 of *dgcM* mRNA (Fig [2](#embj2018101199-fig-0002){ref-type="fig"}A). To assess whether OmrA and/or OmrB can inhibit *dgcM* expression, fluorescence of cells harboring a plasmid encoding a *dgcM::gfp* translational fusion was measured in the presence and absence of plasmids encoding *omrA* or *omrB*. Overexpression of either of the sRNAs strongly decreased fluorescence compared to an empty vector control (Fig [2](#embj2018101199-fig-0002){ref-type="fig"}B), indicating direct repression of DgcM synthesis by the sRNAs. When the same plasmids were introduced into a Δ*hfq* background, regulation was lost (Fig [2](#embj2018101199-fig-0002){ref-type="fig"}B). Note, however that, as for *csgD* (Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}), uninhibited *dgcM* expression was ≈3‐fold lower in a ∆*hfq* than an *hfq* ^+^ background ([Appendix Fig S2A](#embj2018101199-sup-0001){ref-type="supplementary-material"}). Thus, as in many *trans*‐encoded sRNA‐target interactions, Hfq is required for regulation. To assess whether inhibition of *dgcM* is dependent on the predicted base‐pairing interaction, Western blot analysis was performed on cell lysates from *E. coli* cells expressing *dgcM* with a C‐terminal 3xFLAG sequence, combined with OmrA or OmrB overexpression vectors, or their mutant variants OmrA_M2, OmrB_M2 (Fig [2](#embj2018101199-fig-0002){ref-type="fig"}A). Overexpression of wild‐type (wt) OmrA or OmrB strongly decreased DgcM‐3xFLAG signals, congruent with the GFP fusion results (Fig [2](#embj2018101199-fig-0002){ref-type="fig"}B and C). As expected, mismatched OmrA_M2 or OmrB_M2 did not affect DgcM expression, supporting the importance of these nucleotides in base‐pairing to the *dgcM* mRNA (Fig [2](#embj2018101199-fig-0002){ref-type="fig"}A and C). A compensatory mutation in *dgcM*, designed to base‐pair with OmrA_M2 and OmrB_M2, restored regulation for OmrB_M2, but not OmrA_M2 (Fig [2](#embj2018101199-fig-0002){ref-type="fig"}A and C). Mobility shift assays showed binding of OmrA_M2 to both the wt *dgcM* and *dgcM_M2* mRNAs ([Appendix Fig S3](#embj2018101199-sup-0001){ref-type="supplementary-material"}). We therefore hypothesize that OmrA_M2 preferably binds to a second, likely regulatorily inert site. Interestingly, when we supplemented a strain carrying both *csgD* and *ompR* target mutations (Fig [1](#embj2018101199-fig-0001){ref-type="fig"}C) with a plasmid encoding *dgcM‐M2*, thus rendering all known OmrA/B biofilm targets unregulated, biofilm formation was restored in the presence of OmrA, but not OmrB ([Appendix Fig S4A](#embj2018101199-sup-0001){ref-type="supplementary-material"}). It is therefore possible that OmrB may target additional biofilm‐related mRNAs. Taken together, our results indicate that OmrA and OmrB repress DgcM output by direct base‐pairing interaction within the early coding region of the mRNA and that Hfq is required for their effect.

![OmrA and OmrB inhibit *dgcM* expression *in vivo* by direct base‐pairing in an Hfq‐dependent manner\
Predicted base‐pairing between *dgcM* mRNA and OmrA/OmrB. Gray boxes show the M2 point mutation introduced to disrupt the interaction. The UTR is 74 nt long (to AUG), and the interaction site is numbered.Relative fluorescence/OD~600~ of cells of *Escherichia coli* strain MC4100 *relA* ^+^ ∆*omrAB* or MC4100 *relA* ^+^ ∆*omrAB* ∆*hfq* harboring the translational fusion plasmid pDgcM::GFP in combination with plasmids expressing OmrA, OmrB, or an empty control vector, after 16 h of growth at 37°C. Error bars SD, *N* = 3. Average fluorescence intensities (a.u.)/OD~600~ used to calculate ratios can be found in [Appendix Fig S2A](#embj2018101199-sup-0001){ref-type="supplementary-material"}. Note that absolute *dgcM::gfp* expression values are ≈3--4‐fold lower in the ∆*hfq* strain ([Appendix Fig S2B](#embj2018101199-sup-0001){ref-type="supplementary-material"}).Western blot analysis of cell lysates from strains MC4100 *relA* ^+^ ∆*omrAB* harboring plasmids pOmrA, pOmrB, or mutant variants as indicated, in combination with a plasmid expressing C‐terminal FLAG‐tagged *dgcM* or *dgcM_M2*. As a loading control, part of a protein‐stained gel is shown below.](EMBJ-38-e101199-g003){#embj2018101199-fig-0002}

OmrA and OmrB inhibit *dgcM* translation *in vitro* {#embj2018101199-sec-0005}
---------------------------------------------------

The OmrA/OmrB interaction site on *dgcM* is located immediately downstream of the "5‐codon window" within which sRNAs are believed to interfere with 30S ribosomal subunit binding (Bouvier *et al*, [2008](#embj2018101199-bib-0007){ref-type="ref"}). Thus, we tested whether OmrA and OmrB can block initiation complex formation on *dgcM* mRNA. As expected, a characteristic 30S/tRNA~fMet~‐dependent reverse transcription stop ("toeprint") at position +15 was observed, which was absent upon inclusion of OmrA or OmrB (Fig [3](#embj2018101199-fig-0003){ref-type="fig"}A); an unrelated sRNA, IstR‐1 (Vogel *et al*, [2004](#embj2018101199-bib-0084){ref-type="ref"}), failed to inhibit the *dgcM* toeprint.

![OmrA/B inhibit DgcM translation by competing for ribosome binding\
Toeprinting showing inhibition of initiation complex formation on a truncated *dgcM* mRNA (210 nt from +1) by OmrA and OmrB. Inclusion of 30S ribosomes, tRNA~fmet~, OmrA, and OmrB is indicated. The unrelated IstR‐1 sRNA is a negative control. The 30S/tRNA~fmet~‐dependent reverse transcription block (toeprint) is indicated by an arrow. Sequencing reactions were loaded next to the primer extension products (UCGA). The AUG start codon is indicated by asterisks.*In vitro* translation of *dgcM::3xflag* mRNA in the presence or absence of OmrA/OmrB, with or without purified Hfq protein, was carried out as in [Materials and Methods](#embj2018101199-sec-0011){ref-type="sec"}. As an internal control, the non‐target *ompA::3xflag* mRNA was included. The Western blot shows DgcM‐3xFLAG and OmpA‐3xFLAG protein levels.](EMBJ-38-e101199-g004){#embj2018101199-fig-0003}

Translational level regulation was further tested with *in vitro* assays. Here, *dgcM::FLAG* and *ompA::FLAG* mRNAs were used as templates, the latter serving as internal control; this mRNA is not subject to OmrA/B regulation. Upon adding OmrA or OmrB to the reaction, a slight reduction of DgcM translation was observed, with OmrA being reproducibly more effective than OmrB (Fig [3](#embj2018101199-fig-0003){ref-type="fig"}B). Addition of Hfq greatly enhanced the inhibitory effect of both sRNAs, so that DgcM was essentially absent (Fig [3](#embj2018101199-fig-0003){ref-type="fig"}B). *In vivo*, Hfq is required for the stability of OmrA and OmrB (Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}). However, since RNAs are entirely stable in the PURExpress^®^ *In Vitro* Protein Synthesis Kit (Sharma *et al*, [2007](#embj2018101199-bib-0076){ref-type="ref"}), this striking regulatory dependence implies a key role for Hfq in *dgcM* mRNA‐OmrA/B duplex formation.

OmrA/B and *dgcM* mRNA interaction sites {#embj2018101199-sec-0006}
----------------------------------------

The above results suggest that *dgcM* mRNA and OmrA/B directly base‐pair with each other, most likely in close proximity of, or overlapping, the ribosome‐binding site (RBS). To precisely map this interaction, a footprinting analysis was conducted by enzymatic and chemical probing. 5′‐end‐labeled *dgcM* mRNA, ±Hfq, and/or OmrA/B was subjected to limited digestion (on average \< 1 cut/RNA molecule) with RNase T1 (specific for unpaired G residues) or lead(II) acetate (specific for single‐stranded nucleotides; Fig [4](#embj2018101199-fig-0004){ref-type="fig"}A). Binding of Hfq alone protected residues 48--64 (lead‐II cleavage) as well as G54 (RNase T1; Fig [4](#embj2018101199-fig-0004){ref-type="fig"}A and B). This region of the *dgcM* mRNA features the typical (AAN)~n~ motifs known to bind the distal face of Hfq hexamers (Link *et al*, [2009](#embj2018101199-bib-0042){ref-type="ref"}; Robinson *et al*, [2014](#embj2018101199-bib-0066){ref-type="ref"}). Hfq binding also induced minor long‐range structural rearrangements, e.g., 5′ of the main Hfq‐binding site (G32--G39; Fig [4](#embj2018101199-fig-0004){ref-type="fig"}A). Importantly, Hfq binding entailed an opening of the small hairpin that contains the RBS of the *dgcM* mRNA, indicated by enhanced T1 cuts of G66--68 within the SD sequence, and at G83 on the opposite side of the stem. We also observed that residues G101 and G102 showed slightly increased accessibility toward RNase T1 (Fig [4](#embj2018101199-fig-0004){ref-type="fig"}A, lane 6). Unexpectedly, structural probing done with Hfq and either OmrA or OmrB revealed the presence of two adjacent sRNA‐binding sites (Fig [4](#embj2018101199-fig-0004){ref-type="fig"}A, lanes 9--10, and 15--16, indicated by red and blue boxes). Protection of site 1 was identical for both OmrA and OmrB and concurred with the computationally predicted binding site. It spans from position U91 to G102, as shown by complete protection of G101 and G102 from T1 cleavage, and lead‐II protection from U91 to G102 (Fig [4](#embj2018101199-fig-0004){ref-type="fig"}A and B). Site 2 differs between the sRNAs. Both OmrA and OmrB base‐pair from U121 to G125, since G124, G125 (T1), and U121 to G125 (lead‐II) were fully protected in the presence of Hfq and the sRNAs (Fig [4](#embj2018101199-fig-0004){ref-type="fig"}A, lanes 9--10). Binding of OmrA, but not OmrB, extended protection to residues C110 to U123 (lead‐II) and G115 (T1). Incidentally, both OmrA/B binding sites are supported by RIL‐seq results (Melamed, personal communication; Melamed *et al*, [2016](#embj2018101199-bib-0044){ref-type="ref"}). Corresponding and complementary probing was done with labeled OmrA and OmrB ([Appendix Fig S5](#embj2018101199-sup-0001){ref-type="supplementary-material"}). As expected, both sRNAs bind through their conserved 5′ tails, as seen on other mRNA targets (Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}).

![Footprinting of the OmrA/OmrB/Hfq‐binding sites on *dgcM* mRNA by chemical and enzymatic probing\
5′ end‐labeled *dgcM* mRNA (10 nM) was subjected to probing as described in [Materials and Methods](#embj2018101199-sec-0011){ref-type="sec"}. All components added to the labeled RNA are indicated above the autoradiogram. When added, Hfq hexamers were at 50 nM, the sRNAs OmrA and OmrB at 250 nM. The accessibility of each nucleotide was probed with water (lanes 1--4, negative control for RNA integrity), RNase T1, or lead(II) acetate. Lane T1: RNase T1 under denaturing conditions. Lane OH: alkaline ladders. Binding sites of Hfq (green arrows and boxes), and site 1 (red arrows and boxes) and 2 (blue arrows and boxes) of the sRNAs, are highlighted. Note that site 2 is bound differently by OmrA and OmrB (blue boxes on gel). Black boxes indicate Hfq‐dependent T1 cleavage enhancements.Secondary structure of *dgcM* mRNA ± Hfq, based on results in (A). Nucleotides are color‐coded as in (A). Unchanged T1 cleavages are indicated by filled arrows, enhanced T1 cleavages by arrow and star, protection from T1 cleavages by dashed arrows. Lead(II) acetate‐protected sequences are indicated by full (Hfq + OmrA/B), dashed (Hfq + OmrA), or dotted (Hfq alone) frames. In the lower panel, Q = Hfq, A = OmrA, and B = OmrB.](EMBJ-38-e101199-g005){#embj2018101199-fig-0004}

To confirm OmrA/B binding to sites 1 and 2, we performed mobility shift assays with a shorter end‐labeled *dgcM* mRNA and OmrA or OmrB. DNA‐oligos complementary to site 1 or site 2 ([Appendix Fig S6 and Table S1](#embj2018101199-sup-0001){ref-type="supplementary-material"}) were pre‐annealed to the mRNA to block the accessibility of the respective sites to base‐pairing of the sRNAs. When site 1 was blocked, OmrA---but not OmrB---could still bind site 2 (Fig [5](#embj2018101199-fig-0005){ref-type="fig"}). Blocking site 2 still permitted both sRNAs to bind site 1. When both sites were blocked, neither of the sRNAs could bind. Interestingly, in the absence of oligos, OmrA was more efficient in the gelshift than OmrB. Furthermore, a super‐shift was observed with OmrA‐*dgcM* mRNA, indicating that two OmrA molecules were bound to one *dgcM* mRNA. Though binding between OmrA and site 2 clearly occurs *in vitro* (Figs [4](#embj2018101199-fig-0004){ref-type="fig"} and [5](#embj2018101199-fig-0005){ref-type="fig"}), this interaction is likely not of regulatory importance, since point mutations introduced in site 1 alone eliminated regulation completely (Fig [2](#embj2018101199-fig-0002){ref-type="fig"}A and C).

![DNA‐oligo binding to *dgcM* mRNA blocks OmrA and OmrB access\
Mobility shift assay with end‐labeled *dgcM* RNA (210‐nt species from +1) in the presence or absence of unlabeled OmrA or OmrB. When indicated, single‐stranded DNA‐oligos were pre‐annealed to site 1 (dgcM_site1), site 2 (dgcM_site2), or both, before addition of sRNAs. For locations of the binding sites, see [Appendix Fig S6](#embj2018101199-sup-0001){ref-type="supplementary-material"}. The additions for each sample are indicated above the Figure, and the identities of the nucleic acid complexes are indicated on the left for guidance.](EMBJ-38-e101199-g006){#embj2018101199-fig-0005}

Hfq‐dependent restructuring of the *dgcM* mRNA is essential for regulation by OmrA and OmrB {#embj2018101199-sec-0007}
-------------------------------------------------------------------------------------------

Inspection of the predicted *dgcM* 5′ structure based on footprinting results (Fig [4](#embj2018101199-fig-0004){ref-type="fig"}) and the mFold algorithm (Zuker, [2003](#embj2018101199-bib-0096){ref-type="ref"}) suggested that the presumed seed region within the OmrA/B binding site 1 is partially sequestered in a hairpin (Fig [4](#embj2018101199-fig-0004){ref-type="fig"}B, upper structure), likely rendering it difficult to access by the sRNAs. Based on footprinting results (Fig [4](#embj2018101199-fig-0004){ref-type="fig"}A), we hypothesized that Hfq binding unfolds this structure to facilitate sRNA‐mRNA duplex formation (Fig [4](#embj2018101199-fig-0004){ref-type="fig"}B, lower structure). If so, this might explain the strong dependence on Hfq for regulation. However, Hfq is also known to enhance base‐pairing rates by bringing sRNA and mRNA target into close proximity, since it can bind two RNAs simultaneously through its different interaction surfaces. To tease apart the contributions of Hfq in these non‐exclusive models, we performed translation assays, adding Hfq mutant proteins with specific impairments in the proximal (St_Hfq102_F42A), distal (St_Hfq102_Y25A_Q52A), or rim (St_Hfq 102R16S_R17A_R19A_K47E) interaction surface (Sauer *et al*, [2012](#embj2018101199-bib-0074){ref-type="ref"}); the Hfq mutant proteins are subsequently referred to as Hfq‐dist, Hfq‐prox, and Hfq rim. As in Fig [3](#embj2018101199-fig-0003){ref-type="fig"}B, *ompA* mRNA was used as an OmrA/B‐independent internal control.

Figure [6](#embj2018101199-fig-0006){ref-type="fig"}A shows that, at the concentrations used, OmrA or OmrB alone do not significantly inhibit DgcM translation, whereas the inclusion of wt Hfq drives DgcM output down to barely detectable levels. The *dgcM* mRNA, carrying an A‐rich Hfq‐binding motif (+45--65, Fig [4](#embj2018101199-fig-0004){ref-type="fig"}B), is expected to interact with the Hfq distal face (Link *et al*, [2009](#embj2018101199-bib-0042){ref-type="ref"}). Assuming that Hfq‐mediated opening of the inhibitory structure in *dgcM* mRNA is important for OmrA/B binding, mutations affecting the distal face should impair regulation. Indeed, supplementing the *in vitro* translation reaction with a distal face mutant protein strongly impeded OmrA‐dependent regulation, nearly mirroring the absence of Hfq (Fig [6](#embj2018101199-fig-0006){ref-type="fig"}A). In agreement, mobility shift assays showed that, in the presence of Hfq‐dist, very little *dgcM*‐OmrA complex was formed ([Appendix Fig S7](#embj2018101199-sup-0001){ref-type="supplementary-material"}). By contrast, Hfq‐prox or Hfq rim supported strong inhibition by OmrA, and less so by OmrB. Hence, these surfaces are not strictly needed for Hfq\'s regulation‐enhancing effect, whereas distal face interaction on *dgcM* mRNA is required for efficient regulation.

![Effects of mutant or wild‐type Hfq variants, and of an Hfq‐mimic oligo, on OmrA/B regulation of DgcM translation *in vitro*\
Western blots showing DgcM‐3xFLAG translated *in vitro* in the presence or absence of OmrA or OmrB. The inclusion of purified wild‐type or mutant Hfq proteins is indicated, and the translation assay was conducted as in [Materials and Methods](#embj2018101199-sec-0011){ref-type="sec"}. The different Hfq interaction site mutant proteins are indicated.An ssDNA‐oligo (Hfq_BS, [Appendix Table S1](#embj2018101199-sup-0001){ref-type="supplementary-material"}) that base‐pairs specifically to the Hfq‐binding site on *dgcM* mRNA (nt 42--66) was pre‐annealed to the mRNA prior to OmrA/B addition and translation. OmpA‐3xFLAG was included as internal control.Data information: Quantification of DgcM translation rates, relative to that of the unaffected OmpA control, is shown below the gels. The ratio of DgcM/OmpA signal was set to unity for the lane lacking sRNA in each set of three combinations (−sRNA, +OmrA, +OmrB), indicated by "1.00\*". Effects due to OmrA/OmrB addition can be seen by comparing lanes 2 and 3 to lane 1 in each set.](EMBJ-38-e101199-g007){#embj2018101199-fig-0006}

The results in Fig [6](#embj2018101199-fig-0006){ref-type="fig"}A alone do not exclude a simultaneous interaction of either sRNA with Hfq as important for regulation. However, since the proximal face and rim are preferred interaction surfaces for most sRNAs, including OmrA and OmrB (Schu *et al*, [2015](#embj2018101199-bib-0075){ref-type="ref"}), Hfq‐prox and Hfq rim should not interact with the sRNAs, but be still capable of opening the inhibitory structure in *dgcM* mRNA. Mobility shift assays confirmed that OmrA does not bind to Hfq rim but forms a complex with Hfq‐prox ([Appendix Fig S7](#embj2018101199-sup-0001){ref-type="supplementary-material"}). This indicates that for OmrA, akin to some sRNAs like RyhB and RprA, the rim suffices for stable interaction (Sauer *et al*, [2012](#embj2018101199-bib-0074){ref-type="ref"}). More importantly, Hfq rim, unable to bind OmrA ([Appendix Fig S7](#embj2018101199-sup-0001){ref-type="supplementary-material"}), nevertheless supports strong OmrA‐dependent inhibition of DgcM translation (Fig [6](#embj2018101199-fig-0006){ref-type="fig"}A), suggesting that Hfq rim acts here through its intact distal face, similar to Hfq‐wt. Mobility shift assays indeed show Hfq rim promoted OmrA‐*dgcM* mRNA complex formation, but---unlike with Hfq‐wt and Hfq‐prox---no slowly migrating ternary complexes ([Appendix Fig S7](#embj2018101199-sup-0001){ref-type="supplementary-material"}). Taken together, Hfq distal face binding to *dgcM* mRNA is most important for regulation, whereas binding of Hfq to OmrA/B, and its effect on annealing, may be less important or not required.

Forced opening of the inhibitory structure is sufficient to enhance regulation {#embj2018101199-sec-0008}
------------------------------------------------------------------------------

Based on the above results, a forced opening of the structure that hinders OmrA/B access might bypass the Hfq requirement. We chose to mimic Hfq binding by annealing of a DNA‐oligo with complementarity to the Hfq‐binding site in *dgcM* ([Appendix Table S1 and Fig S6](#embj2018101199-sup-0001){ref-type="supplementary-material"}). Indeed, a *dgcM* mRNA annealed to the Hfq‐mimic oligo was substantially inhibited by both OmrA and OmrB in the complete absence of Hfq (Fig [6](#embj2018101199-fig-0006){ref-type="fig"}B). The inhibition by OmrA/B was roughly comparable to that obtained in the presence of Hfq (cf. Fig [6](#embj2018101199-fig-0006){ref-type="fig"}B and A, lanes 4--6) and significantly stronger than in its absence (Fig [6](#embj2018101199-fig-0006){ref-type="fig"}A, lanes 1--3). Altogether, this suggests that---in the case of OmrA/B regulation of *dgcM*---an "interaction platform" involving the binding of both interacting RNAs is not required. Rather, the major role of Hfq lies in converting an mRNA structure element into an sRNA‐accessible site (cf. structures in Fig [4](#embj2018101199-fig-0004){ref-type="fig"}B). This inference predicts that OmrA/B association rates should be higher upon structure opening. Mobility shift assays with labeled OmrA and *dgcM* mRNA, or *dgcM* mRNA with the pre‐annealed mimic oligo, indeed showed association rates effects; second‐order binding rate constants for OmrA to *dgcM* were about three times higher in presence of the oligo ([Appendix Fig S8](#embj2018101199-sup-0001){ref-type="supplementary-material"}).

In conclusion, the Hfq requirement for regulation can be largely bypassed by binding of a DNA‐oligo that opens a local structure in the *dgcM* mRNA. Thus, the predominant function of this RNA chaperone lies in unfolding *dgcM* mRNA to render its target region more rapidly accessible to OmrA/B.

The Hfq distal surface is required for OmrA/B‐dependent regulation of DgcM *in vivo* {#embj2018101199-sec-0009}
------------------------------------------------------------------------------------

To assess the contribution of the Hfq‐binding surfaces on regulation *in vivo*, we introduced the *dgcM::gfp* translational fusion plasmid into *E. coli* strains harboring chromosomal *hfq‐*F42A, *hfq‐*Y25D, *hfq‐*R16S_R17A_R19A_K47E mutant alleles, as well as in a wild‐type and a *∆hfq* strain. Flow cytometric analyses of these cells, carrying or lacking *omrA* or *omrB* expression plasmids, showed that---in line with Fig [2](#embj2018101199-fig-0002){ref-type="fig"}---regulation was abolished in a *∆hfq* background. Interestingly, regulation was also lost in the distal face mutant (*hfq‐*Y25D) strain (Fig [7](#embj2018101199-fig-0007){ref-type="fig"}A), in spite of even slightly higher sRNAs levels than in the wild‐*type hfq* strain (Fig [7](#embj2018101199-fig-0007){ref-type="fig"}B; cf. *hfq* wt and *hfq*‐dist). These results are congruent with the *in vitro* experiment in Fig [6](#embj2018101199-fig-0006){ref-type="fig"}A and support that the Hfq distal face is required for remodeling of the *dgcM* mRNA and regulation also in an intracellular environment. In apparent contrast to the *in vitro* translation experiment (Fig [6](#embj2018101199-fig-0006){ref-type="fig"}A), *hfq* proximal and rim mutations fail to support regulation of *dgcM* by OmrA and OmrB *in vivo* (Fig [7](#embj2018101199-fig-0007){ref-type="fig"}A). This is however tentatively explained by the strongly reduced stability of the sRNAs in these mutant strains (Fig [7](#embj2018101199-fig-0007){ref-type="fig"}B).

![The Hfq distal face is essential for OmrA/B‐dependent regulation of *dgcM in vivo*\
Histograms show flow cytometry analysis of exponentially growing cells of *Escherichia coli* strain MC4100 *relA* ^−^, and its mutant derivatives *hfq‐*F42A (*hfq‐*prox), *hfq‐*Y25D (*hfq‐*dist), *hfq‐*R16S_R17A_R19A_K47E (*hfq‐*rim), *∆hfq*, harboring the translational fusion plasmid pDgcM::GFP in combination with pOmrA, pOmrB, or a control vector. Data were obtained on a MACSQuant VYB instrument.Northern blot analysis of total RNA isolated from the same cultures at the same time point as used for flow cytometry, probed for OmrA (strains containing pOmrA) or OmrB (strains containing pOmrB). 5S rRNA was used as loading control.](EMBJ-38-e101199-g008){#embj2018101199-fig-0007}

In conclusion, the distal face of the Hfq hexamer is essential for OmrA/B‐dependent regulation of *dgcM* both *in vitro* and *in vivo*. This likely reflects that the Hfq distal surface interaction with the *dgcM* mRNA promotes local unfolding, exposing the seed region for OmrA and OmrB interaction and facilitating sRNA‐mRNA duplex formation.

Discussion {#embj2018101199-sec-0010}
==========

In this report, we identified *dgcM*, encoding an upstream regulator of the biofilm signaling pathway in *E. coli*, as a target of the sRNAs OmrA and OmrB, thus adding to the complexity of the sRNA network in control of biofilm formation (Boehm *et al*, [2010](#embj2018101199-bib-0005){ref-type="ref"}; Fig [1](#embj2018101199-fig-0001){ref-type="fig"}A). As suggested by Mika and Hengge ([2013](#embj2018101199-bib-0046){ref-type="ref"}, [2014](#embj2018101199-bib-0047){ref-type="ref"}), OmrA/B regulation of *dgcM*, as well as *csgD*, might be important to prevent expression of biofilm components under stationary‐phase conditions where RpoS is active, and may be critical in the decision to convert from a motile planktonic to a biofilm lifestyle. Inhibition of DgcM translation *in vivo* and *in vitro* occurs by direct base‐pairing within the early coding region, as defined by effects of mutations in site 1 (Fig [2](#embj2018101199-fig-0002){ref-type="fig"}). Though OmrA/B pulse expression causes a strong decrease in *dgcM* mRNA levels (Hoekzema, Holmqvist, in preparation), the demonstration that the sRNAs inhibit initiation complex formation (Fig [3](#embj2018101199-fig-0003){ref-type="fig"}A) and *in vitro* translation (Fig [3](#embj2018101199-fig-0003){ref-type="fig"}B) indicates translation inhibition to be the dominant effect. As is true for many other sRNA‐mRNA combinations, regulation of *dgcM* by OmrA/B is dependent on the RNA chaperone Hfq. This applies not only *in vivo*, where Hfq is needed to stabilize these sRNAs (Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}), but also *in vitro* (Fig [6](#embj2018101199-fig-0006){ref-type="fig"}A) where stabilization effects are ruled out.

Enzymatic and chemical structure probing of the *dgcM* mRNA combined with *in silico* structure predictions (mFold; Zuker, [2003](#embj2018101199-bib-0096){ref-type="ref"}) indicated that OmrA/B binding site 1, on which regulation depends (Fig [2](#embj2018101199-fig-0002){ref-type="fig"}A and C), is partially sequestered in a stem--loop (Fig [4](#embj2018101199-fig-0004){ref-type="fig"}). This suggested a role for Hfq as an RNA remodeler to facilitate OmrA/B binding. The Hfq‐binding site was mapped upstream of the *dgcM* SD and AUG, located opposite of sRNA site 1 in the local structure (Fig [4](#embj2018101199-fig-0004){ref-type="fig"}B). Indeed, an enhanced T1 cleavage of *dgcM* nucleotides G101 and G102 was observed when Hfq was bound, indicative of stem--loop destabilization (Fig [4](#embj2018101199-fig-0004){ref-type="fig"}). These residues became protected upon OmrA/B binding. *In vitro* translation experiments with *dgcM* mRNA, in presence or absence of OmrA/B, and with inclusion of wt or Hfq mutant proteins, pointed toward a requirement of Hfq distal face binding to the *dgcM* mRNA for OmrA/B‐dependent inhibition (Fig [6](#embj2018101199-fig-0006){ref-type="fig"}A). By contrast, mutations in the proximal or rim surfaces had only minor effects on regulatory efficiency. From this, we infer that the predominant role of Hfq---in this case---lies in RNA structure remodeling. Strikingly, when this protein was substituted by an Hfq‐mimic oligo, which base‐paired to the mapped Hfq‐binding site in *dgcM* mRNA, it restored inhibition by OmrA and OmrB in complete absence of Hfq (Fig [6](#embj2018101199-fig-0006){ref-type="fig"}B). Qualitatively supporting the above conclusions, binding rate determinations showed that oligo‐bound *dgcM* mRNA indeed was more readily accessible to OmrA binding than the free mRNA ([Appendix Fig S8](#embj2018101199-sup-0001){ref-type="supplementary-material"}). However, the only ≈three‐fold effect measured and the low association rates obtained do not quantitatively match the stronger effects seen in the translation assay (Fig [6](#embj2018101199-fig-0006){ref-type="fig"}B). At this point, this discrepancy is unexplained but may be related to the different assay conditions---a single‐step reaction ([Appendix Fig S8](#embj2018101199-sup-0001){ref-type="supplementary-material"}) versus inhibition in multiple rounds of translation (Fig [6](#embj2018101199-fig-0006){ref-type="fig"}B). Supporting the *in vitro* translation results (Fig [6](#embj2018101199-fig-0006){ref-type="fig"}A), a distal face mutant Hfq was unable to support OmrA/B‐dependent regulation of *dgcM::gfp in vivo*, even though the sRNA levels were high (Fig [7](#embj2018101199-fig-0007){ref-type="fig"}A and B). For the proximal and rim Hfq mutant, the *in vitro* and *in vivo* results differed, which however is readily explained. The two corresponding mutant strains fail to accumulate high sRNA levels (Fig [7](#embj2018101199-fig-0007){ref-type="fig"}B), as has been observed for many class 1 sRNAs (e.g., Schu *et al*, [2015](#embj2018101199-bib-0075){ref-type="ref"}), which results in loss of regulation. We conclude that, in contrast to several other mRNA‐sRNA pairs, OmrA/B‐*dgcM* mRNA complex formation relies on Hfq distal face binding both *in vitro* and *in vivo*, causing a subsequent restructuring of the *dgcM* mRNA, to facilitate OmrA/B association. Based on our *in vitro* results (Fig [6](#embj2018101199-fig-0006){ref-type="fig"}A), proximal and rim interactions contribute only marginally to regulation.

The capability of the RNA chaperone Hfq to locally unwind and/or restructure bound RNAs is well established and hardly surprising (e.g., Woodson *et al*, [2018](#embj2018101199-bib-0090){ref-type="ref"}). Remodeling has been demonstrated for the sRNAs OxyS, RprA, and DsrA (Zhang *et al*, [2002](#embj2018101199-bib-0093){ref-type="ref"}; Vecerek *et al*, [2008](#embj2018101199-bib-0081){ref-type="ref"}; Ribeiro Ede *et al*, [2012](#embj2018101199-bib-0065){ref-type="ref"}; Henderson *et al*, [2013](#embj2018101199-bib-0027){ref-type="ref"}), as well as the *ompA*,*sodB,* and *mutS* mRNAs (Moll *et al*, [2003b](#embj2018101199-bib-0049){ref-type="ref"}; Geissmann & Touati, [2004](#embj2018101199-bib-0019){ref-type="ref"}; Chen & Gottesman, [2017](#embj2018101199-bib-0013){ref-type="ref"}). In the case of *mutS,* Hfq inhibits translation through both sRNA‐dependent and sRNA‐independent mechanisms. While the sRNA ArcZ inhibits translation by base‐pairing to the *mutS* 5′UTR, Hfq distal face binding remodels the mRNA leader to induce an inhibitory structure in the translation initiation region (Chen & Gottesman, [2017](#embj2018101199-bib-0013){ref-type="ref"}). However, these structural changes do not seem to affect inhibition of *mutS* by its regulator ArcZ; downregulation by ArcZ is almost as strong in an Hfq distal face mutant strain as in the wild‐type (Chen & Gottesman, [2017](#embj2018101199-bib-0013){ref-type="ref"}).

Hfq‐dependent remodeling of mRNA as a requirement for sRNA interaction has specifically been proposed for RyhB regulation of *sodB* (Geissmann & Touati, [2004](#embj2018101199-bib-0019){ref-type="ref"}). We noted however that, while Hfq‐dependent structure remodeling of the *sodB* mRNA was demonstrated, the expected faster binding of RyhB to *sodB* mRNA in the presence of Hfq has not been experimentally tested. Neither has the effect of Hfq on translation initiation, or overall translation, been examined, thus rendering the mechanistic interpretations ambiguous (Geissmann & Touati, [2004](#embj2018101199-bib-0019){ref-type="ref"}). Moreover, the conclusions from this publication are at odds with another study of the same sRNA‐target system (Hao *et al*, [2011](#embj2018101199-bib-0026){ref-type="ref"}). Here, a truncated RyhB variant, RyhBt, which is entirely Hfq‐independent and stable in the absence of Hfq, was fully active in *sodB* expression control *in vivo*. Thus, whether remodeling of *sodB* mRNA is the critical event for regulation by RyhB, as proposed in Geissmann and Touati ([2004](#embj2018101199-bib-0019){ref-type="ref"}), needs to be addressed by further experiments. Hfq‐induced structural changes have also been reported for *ompA* mRNA, but it remains unknown whether they are required for duplex formation with targeting sRNAs (Moll *et al*, [2003b](#embj2018101199-bib-0049){ref-type="ref"}).

The *cis*‐encoded RNA‐IN and RNA‐OUT system (transposon *Tn*10/*IS*10) also involves secondary structure rearrangements brought about by Hfq binding, suggested to explain how Hfq facilitates RNA‐IN:OUT pairing (Ross *et al*, [2013](#embj2018101199-bib-0069){ref-type="ref"}). So far, the functional implications of these rearrangements are not entirely clear, in particular since an Hfq‐independent binding pathway involving kissing loop interactions is known (Ross *et al*, [2013](#embj2018101199-bib-0069){ref-type="ref"}), and protein‐free association rate constants of RNA‐IN and RNA‐OUT (0.5 × 10^6^ M^−1^ s^−1^; Ma & Simons, [1990](#embj2018101199-bib-0043){ref-type="ref"}) are \> 100‐fold faster than those typical for *trans‐*encoded sRNAs (Wagner & Romby, [2015](#embj2018101199-bib-0087){ref-type="ref"}). This is different from our model, in that functional OmrA/B‐*dgcM* mRNA interactions barely occur in the absence of Hfq ([Appendix Fig S7](#embj2018101199-sup-0001){ref-type="supplementary-material"}). Though we propose that *dgcM*‐OmrA/B is a first case in which this mechanism has been experimentally validated, other systems, like those above and others, may indeed work similarly. For example, regulation of *dgcM* mRNA by RprA (Mika *et al*, [2012](#embj2018101199-bib-0045){ref-type="ref"}) appears to occur at a binding site close to that of OmrA/B, and hence might conform to the same model.

A surprising finding was the ability of OmrA/B to protect *dgcM* mRNA from *in vitro* cleavage at two distinct but adjacent sites (Fig [4](#embj2018101199-fig-0004){ref-type="fig"}). Two‐site recognition by one sRNA has previously been reported for the *lpxR* and *nhaB* mRNAs. In both cases, binding to one site overlapping the RBS blocks translation by competing with initiating ribosomes, whereas binding to the second site far downstream in the coding region induces RNase E‐mediated cleavage (Corcoran *et al*, [2012](#embj2018101199-bib-0015){ref-type="ref"}; Chao & Vogel, [2016](#embj2018101199-bib-0012){ref-type="ref"}). Here, only OmrA/B binding site 1 (nt 88--102) in *dgcM* is associated with inhibition (Fig [3](#embj2018101199-fig-0003){ref-type="fig"}A and B) since mutations that weaken this interaction suffice to abolish regulation *in vivo* (Fig [2](#embj2018101199-fig-0002){ref-type="fig"}A and C). In light of these data, a regulatory role for site 2 seems unlikely.

In conclusion, the present analysis identified OmrA/B as regulators of yet another target within the biofilm pathway of *E. coli*, DgcM. More importantly, we uncovered a different and new mechanism of action for Hfq. Instead of acting as a canonical platform for simultaneous sRNA‐mRNA binding, Hfq acts here---exclusively or at least primarily---by opening a local target structure in the *dgcM* mRNA to provide access to the regulatory sRNAs. The *in vitro* data strongly support these conclusions, although it cannot be ruled out that, e.g., a platform role of Hfq may contribute to *in vivo* activity. We suggest that it might be fruitful to search for similar examples of Hfq‐dependent regulation in which this protein\'s RNA structure‐remodeling activity, rather than its annealing function or duplex‐stabilizing effect, plays the dominant role.

Materials and Methods {#embj2018101199-sec-0011}
=====================

Chemicals, reagents, and oligodeoxyribonucleotides {#embj2018101199-sec-0012}
--------------------------------------------------

Growth media components were purchased from Oxoid. Oligodeoxyribonucleotides/primers ([Appendix Table S1](#embj2018101199-sup-0001){ref-type="supplementary-material"}) and chemicals were purchased from Sigma‐Aldrich, and reagents from Thermo Fisher Scientific.

Growth conditions {#embj2018101199-sec-0013}
-----------------

Bacterial cells were grown aerobically at 37°C in L Broth. When applicable, antibiotics were added at 100 (ampicillin), 50 (kanamycin), or 15 μg/ml (chloramphenicol and tetracycline). For detection of curli expression, Congo Red plates (LA plates without NaCl, 20 μg/ml Congo red, 10 μg/ml Coomassie Brilliant Blue G) were used. Plates were incubated at 28°C for 24 h.

Bacterial strains and plasmids {#embj2018101199-sec-0014}
------------------------------

All strains used in this study are derivatives of *E. coli* K12 MC4100 *relA* ^+^, unless otherwise stated. Strains and plasmids are listed in [Appendix Tables S2 and S3](#embj2018101199-sup-0001){ref-type="supplementary-material"}, respectively.

Plasmids pOmrA, pOmrB, and pControl were previously published (Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}). Plasmid pDgcM::GFP was constructed by inserting a *Ns*iI/*Nhe*I‐digested PCR product (primers EHO‐759/EHO‐760) into *Ns*iI/*Nhe*I‐digested pXG10‐SF, fusing 641 bp from the transcription start site to *gfp*. pXG10‐SF is identical to pXG‐10 (Urban & Vogel, [2007](#embj2018101199-bib-0080){ref-type="ref"}) except for substitution of *gfp* by *sfgfp*. Plasmid pDgcM::3xFLAG was created by insertion of *dgcM::*3xFLAG between the *lac* promoter sequence and the terminator sequence on the pXG‐10 vector, thereby replacing *gfp*: the *dgcM*::3xFLAG fragment was amplified from pET52‐b_dgcM_FLAG (see below) with primers MHO‐259 and MHO‐260, introducing *Xba*I and *Pst*I restriction sites, and after digestion with both enzymes, ligated into *Xba*I/*Nsi*I digested pXG‐10. Plasmids pOmrA_M2 and pOmrB_M2 were created using inverse PCR mutagenesis, with the desired mutations included in the primers (MHO‐221/MHO‐223 for OmrA/OmrB, respectively, and MHO‐222). Briefly, after PCR amplification with the phosphorylated primers, pOmrA or pOmrB template DNA was digested by *Dpn*I, PCR product was purified (GeneJET PCR Purification Kit Thermo Fisher Scientific) and religated with Ready‐to‐go T4 ligase (Amersham). The pDgcM_M2::3xFLAG plasmid was created with primers MHO‐217 and MHO‐218 on pDgcM::3xFLAG as template. To create a ∆*dgcM* strain, *dgcM* was replaced by a FRT‐flanked Amp^R^ cassette by Lambda Red recombination (Yu *et al*, [2000](#embj2018101199-bib-0092){ref-type="ref"}) using primers MHO‐094 and MHO‐095. For *dgcM* transcription, a plasmid with a T7‐promoter, *dgcM* ORF*,* a FLAG‐tag, and T7‐terminator was constructed (pET52‐b_dgcM_FLAG) from the pET52‐b vector (Novagen) backbone, already carrying a T7‐promoter and terminator sequence. The plasmid was linearized by PCR using primers MHO‐238 and MHO‐239, introducing a FLAG‐tag and *Xho*I/*Aat*II restriction sites while deleting the His‐tag and multiple cloning site. The *dgcM* 5′ UTR and ORF lacking its stop codon were PCR amplified with primers MHO‐242/MHO‐243, introducing *Xho*I/*Aat*II restriction sites. After digestion with both enzymes, vector and *dgcM* insert were ligated. *E. coli* Top10 cells were used for transformations (Invitrogen).

The *csgD:M4* and *ompR:mut2* mutations were introduced into strain MC4100 by Lambda red recombination (Yu *et al*, [2000](#embj2018101199-bib-0092){ref-type="ref"}) using plasmid pSim5‐tet (Koskiniemi *et al*, [2011](#embj2018101199-bib-0037){ref-type="ref"}). First, a *kan‐sacB* cassette (Pietsch *et al*, [2017](#embj2018101199-bib-0062){ref-type="ref"}), amplified with primers MHO‐100/MHO‐101 for *csgD:M4,* and MHO‐268/MHO‐269 for *ompR:mut2*, was inserted at the site of mutagenesis. A second round of recombination was done with a ssDNA fragment carrying the desired point mutation, followed by counterselection for SacB (Ellis *et al*, [2001](#embj2018101199-bib-0103){ref-type="ref"}). To create the double mutant, *ompR:mut2* was introduced into a wt as well as the *csgD:M4* background.

The F42A (prox) and Y25D (dist) *hfq* mutant strains were previously published (Zhang *et al*, [2013](#embj2018101199-bib-0095){ref-type="ref"}; [Appendix Table S2](#embj2018101199-sup-0001){ref-type="supplementary-material"}). The R16S‐R17A‐R19A‐K47E (rim) mutation, as well as an *hfq* deletion, was introduced into the chromosome of the same MC4100 *relA* ^−^ strain background. This was done by replacing the *cat‐sacB* cassette in MC4100 *relA* ^−^ *∆hfq::cat‐sacB* (Zhang *et al*, [2013](#embj2018101199-bib-0095){ref-type="ref"}), with a PCR fragment carrying the rim mutation, amplified from plasmid pETM60‐St_Hfq102_R16S_R17A_R19A_K47E (Sauer *et al*, [2012](#embj2018101199-bib-0074){ref-type="ref"}) using primers MHO‐294 and MHO‐295, or with an oligo matching the *hfq* flanking region (MHO‐291). The resulting strains were transformed with plasmids pDgcM::GFP and either pOmrA, pOmrB, or pControl.

Fluorescence measurements {#embj2018101199-sec-0015}
-------------------------

For bulk measurements, bacterial cultures grown overnight from single colonies were diluted 1:100 in fresh LB medium and grown in 96‐well black assay plates with clear flat bottom (Costar^®^) at 37°C. Fluorescence (GFP: excitation 480 nm, emission 520 nm) and optical density (600 nm) were measured for 23 h at 5‐min intervals in a plate reader (Tecan Infinite Pro). Corrected fluorescence values were calculated as ratios between fluorescence and OD~600~. To account for cellular auto‐fluorescence, GFP/OD~600~ from a strain not expressing a fluorescent protein was subtracted. Background‐subtracted GFP/OD~600~ values from each strain and time point were averaged and expressed relative to the corresponding strain transformed with the control plasmid lacking an sRNA gene.

Single‐cell analysis of GFP fluorescence was conducted by flow cytometry on a MACSQuant^®^ VYB instrument (Miltenyi Biotec). Cells were diluted in sterile‐filtered PBS and loaded in a 96‐well assay plate for analysis. GFP was excited with a blue laser (488 nm) in channel B1 (bandpass filter 525/50). For each sample, 100,000 events were recorded. The acquired data were processed with FlowJo software (FlowJo LLC) as follows. To exclude background noise, the events were first gated for bacterial cells based on side scatter measurements. Subsequently, the GFP fluorescence for the gated population was plotted as a histogram.

*In vitro* transcription of RNA {#embj2018101199-sec-0016}
-------------------------------

OmrA and OmrB DNA templates containing a T7 promoter, as well as a hammerhead ribozyme sequence, were generated as previously described (Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}). OmrA_M2 was generated similarly using primers MHO‐248 and MHO‐249. To generate a 210 nt *dgcM* mRNA for structure probing and toeprinting assays, DNA templates containing a T7 promoter sequence were generated by PCR using primers MHO‐159/MHO‐194 with *E. coli* MC4100 *relA* ^+^ DNA as a template. The DNA templates were used for *in vitro* transcription using the Megascript Kit (Life Technologies, \#AM1330). Transcription reactions were DNase I‐treated (Roche) for 30 min at 37°C, followed by phenol--chloroform extraction and ethanol precipitation. RNAs were purified from denaturing polyacrylamide‐urea gels by elution into 300 mM sodium acetate, 0.1% SDS, and 1 mM EDTA. After phenol--chloroform extraction, ethanol precipitation, washing with 80% ethanol, and drying, RNA was dissolved in TE buffer. RNA concentration and quality was assessed by NanoDrop and Denaturing PAGE.

5′ end‐labeling was performed on CIAP‐treated RNA (Invitrogen™, \#18009‐019) with T4 PNK (Thermo Fisher Scientific, \#EK0031) and \[γ‐P^32^\]ATP (10 mCi/ml, 3,000 Ci/mmol). Labeled RNAs were gel‐purified as above. Before use, RNAs were refolded in water for 1 min at 95°C followed by 1‐min incubation on ice and renatured for 5 min at 37°C in renaturation buffer (100 mM K‐acetate, 10 mM Mg‐acetate, 50 mM HEPES‐NaOH pH 7.5).

For *in vitro* translation assays, *ompA* and *dgcM* RNAs including C‐terminal FLAG‐tag and terminator sequences were used. PCR template for *ompA*‐FLAG RNA transcription was generated using primers MHO‐207 and MHO‐230 from DNA of strain MC4100 *ompA‐FLAG*. This strain was created by flipping the kanamycin resistance cassette out of strain E388 (Holmqvist *et al*, [2010](#embj2018101199-bib-0029){ref-type="ref"}) using the pCP20 plasmid. For *dgcM* transcription, the PCR fragment used contained the T7 promoter, the FLAG‐tagged *dgcM* sequence, and a T7 terminator (template pET52b_dgcM_FLAG, primers MHO‐244/MHO‐245).

RNA secondary structure probing {#embj2018101199-sec-0017}
-------------------------------

Structural probing was carried out on 5′ end‐labeled RNA. Reactions were performed at 37°C in the presence of 1 μg carrier yeast tRNA. When applicable, OmrA/B binding to *dgcM* RNA was allowed for 15 min in presence or absence of Hfq hexamers (50 nM). Enzymatic probing was done with 0.1 unit of RNAse T1 (Invitrogen™, \#AM22^®^83) for 5 min, stopped by addition of cold Na‐acetate (0.3 M), followed by phenol/chloroform/isoamyl alcohol (25/24/1) extraction. Chemical probing was done with lead(II) acetate at a final concentration of 5 mM for 5 min. Reactions were stopped with cold EDTA (50 mM final concentration). After precipitation, RNAs pellets were dried and dissolved in loading dye. Samples were resolved on 7.5% sequencing gels, fixed for 5 min (10% ethanol, 6% acetic acid), transferred to 3‐mm Whatman paper, and dried. Signals were detected using a PhosphorImager screen and a PMI scanner™ (Bio‐Rad).

Toeprinting assays {#embj2018101199-sec-0018}
------------------

Final concentrations in 10 μl toeprinting reactions were 20 nM of mRNA and, when present, 100 nM of 30S subunits, 300 nM of initiator tRNA, and 0.5 mM of dNTPs. Briefly, mRNAs were denatured for 1 min at 90°C with radiolabeled primers and dNTPs in 1× RT‐buffer (10 mM Tris acetate pH 7.6, 100 mM K‐acetate, 1 mM DTT). After 1 min on ice, Mg‐acetate was added to 10 mM final concentration. RNAs were refolded for 5 min, followed by addition of activated 30S (15 min at 37°C in 1× RT‐buffer). After 10 min, initiator tRNA was added, and incubation continued for 25 min. Reverse transcription was started by addition of 100 U of SSIV (Invitrogen™, \#18090010) for 20 min. Reactions were stopped by cold STOP buffer (50 mM Tris--HCl pH 7.5, 0.1% SDS, 10 mM EDTA). After phenol/chloroform extraction, the RNA template was removed by KOH treatment for 3 min at 95°C. After base neutralization with acetic acid, the cDNAs were ethanol‐precipitated, centrifuged, dissolved in loading buffer, and resolved on 7.5% sequencing gels. Gels were fixed and treated as above.

Gel mobility shift assay {#embj2018101199-sec-0019}
------------------------

5′ end‐labeled refolded RNA was incubated at various concentrations of unlabeled complementary RNA, in presence or absence of Hfq, for 30 min at 37°C. Reactions were stopped by adding loading dye (48% glycerol, 0.01% xylene cyanol, 0.01% bromophenol blue), and samples directly loaded on a 5% non‐denaturing PA‐gel. To avoid heat‐induced duplex separation, gels were run at 4°C for 3 h (300 V) in 0.5× TEB. Gel transfer and analysis was as above. When blocking oligonucleotides were used (Fig [5](#embj2018101199-fig-0005){ref-type="fig"}), they were included in the denaturation and refolding steps of the RNAs.

*In vitro* translation assay {#embj2018101199-sec-0020}
----------------------------

*In vitro* translation assays (reaction volumes 10 μl) were done in the PURExpress^®^ *In Vitro* Protein Synthesis Kit (New England BioLabs), with *dgcM* mRNA containing a FLAG‐tag and terminator sequence. The *dgcM‐FLAG* RNA was first diluted in 3 μl HMK (10 mM HEPES‐NaOH pH 7.5, 10 mM Mg‐acetate, 100 mM K‐acetate). When indicated, *ompA‐FLAG* RNA, OmrA or OmrB, and Hfq protein were included in this 3 μl volume. Final RNA concentrations were 10 nM *dgcM‐FLAG*, 0.3 nM *ompA‐FLAG*, and 500 nM OmrA or OmrB. Hfq protein was included at 18 nM (hexamer). The wild‐type Hfq used was His‐tagged, from *E. coli* strain BL21(DE3)pLys with plasmid pTE607 (Fender *et al*, [2010](#embj2018101199-bib-0018){ref-type="ref"}). In Fig [6](#embj2018101199-fig-0006){ref-type="fig"}A, we used the functionally equivalent *Salmonella Typhimurium* Hfq proteins, wild‐type or with mutations as indicated (St_Hfq102; wild‐type), proximal (St_Hfq102_F42A), distal (St_Hfq102_Y25A_Q52A), or rim (St_Hfq 1 02‐R1 6S‐R1 7A‐R1 9A‐K47 E; Sauer *et al*, [2012](#embj2018101199-bib-0074){ref-type="ref"}). The Hfq‐mimic oligo (Hfq_BS; [Appendix Table S1](#embj2018101199-sup-0001){ref-type="supplementary-material"}) used in Fig [6](#embj2018101199-fig-0006){ref-type="fig"}B was used at a final concentration of 50 nM.

RNAs and Hfq were pre‐incubated for 5 min at 37°C before adding 7 μl of pre‐mixed PURExpress solution A (4 μl) and B (3 μl). After 30 min at 37°C, 2.5 μl of 4× Laemmli sample buffer (Bio‐Rad) was added, on ice. Detection of 3xFLAG‐tagged DgcM and OmpA protein products was as described below.

Western blot analysis {#embj2018101199-sec-0021}
---------------------

Aliquots were withdrawn from cultures at OD~600~ of 0.3 and 0.5, spun down, and pellets resuspended in 1× loading dye \[4× Laemmli sample buffer (Bio‐Rad), 1/10 volume of β‐mercaptoethanol added before use\]. Samples were incubated for 5 min at 95°C before gel electrophoresis. Proteins were separated on an Any kD™ Mini‐PROTEAN^®^ TGX Stain‐Free™ Gel (Bio‐Rad), followed by fluorescent detection of total protein by ChemiDoc™ MP (Bio‐Rad) and the "Any kD™ Mini‐PROTEAN^®^ TGX Stain‐Free™ Gel" application. Then, proteins were transferred to a PVDF membrane with the Trans‐Blot Turbo™ Mini PVDF transfer Packs (Bio‐Rad) and the Trans‐Blot Turbo Transfer System (Bio‐Rad) using the "Any Kd" preset. After o/n blocking in Odyssey^®^ Blocking Buffer (PBS; LI‐COR) at 4°C, membranes were incubated for 1 h with monoclonal ANTI‐FLAG M2‐Peroxidase (HRP) mouse antibody (Sigma; cat. nr. A8592) at r.t., followed by three washes with PBS‐T, and two with PBS. Blots were developed with Amersham™ ECL™ Prime Western Blotting Detection Reagent (GE Healthcare) and imaged using ChemiDoc™ MP (Bio‐Rad) with Chemi Hi Resolution application. Images were analyzed with Image Lab Software (version 4.0 build 16); the quantification of band intensities in Fig [6](#embj2018101199-fig-0006){ref-type="fig"} used equal‐sized squares and pixel counts for background, DgcM, and OmpA.

Northern blot analysis {#embj2018101199-sec-0022}
----------------------

Samples of exponential‐phase liquid cultures were withdrawn and mixed with 0.25 volume of stop solution (95% ethanol, 5% phenol). Cells were pelleted by centrifugation and frozen in liquid nitrogen. After thawing on ice, total RNA was isolated by the hot acid‐phenol method (Blomberg *et al*, [1990](#embj2018101199-bib-0101){ref-type="ref"}). 5 μg of extracted total RNA was mixed with 2× RNA loading buffer \[95% (v/v) formamide, 0.025% (w/v) bromophenol blue, 0.025% (w/v) xylene cyanol\], heated for 2 min at 95°C, and separated on an 8% sequencing gel. After electrophoresis (Bio‐Rad Trans‐Blot cell), RNA was transferred to an Amersham Hybond^™^‐N^+^ membrane (GE Healthcare) by electro‐blotting, and UV‐crosslinked. 5′‐end‐labeled oligodeoxyribonucleotide probes were used for detection of OmrA (EHO‐406), OmrB (EHO‐407) and, as loading control, 5S rRNA (EHO‐690). Prehybridization and hybridization of the membrane were carried out in modified Church and Gilbert hybridization buffer (Church & Gilbert, [1984](#embj2018101199-bib-0102){ref-type="ref"}), at 42°C. For visualization of bands, a Personal Molecular Imager (PMI---Bio‐Rad) was used.
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